Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes

Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate

(2015) Thorsten Bartsch et al.   ANNALS OF NEUROLOGY

Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke

(2014) Jens Neumann et al.   ACTA NEUROPATHOLOGICA

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

(2014) O. Tuohy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab

(2014) Reuben Mari Valenzuela et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

(2014) Gavin Giovannoni et al.   LANCET NEUROLOGY

Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study

(2014) Neda Ebrahimi et al.   Multiple Sclerosis Journal

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

(2014) G. Karlsson et al.   NEUROLOGY

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program

(2014) Paul Emery et al.   PLoS One

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab

(2014) Marinella Clerico et al.   JAMA Neurology

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

(2014) Mikael Cohen et al.   JAMA Neurology

The essential role of t cells in multiple sclerosis: A reappraisal

(2014) CrisS Constantinescu et al.   Biomedical Journal

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients

(2013) A. J. Fine et al.   CLINICAL INFECTIOUS DISEASES

Neutrophil cell surface receptors and their intracellular signal transduction pathways

(2013) Krisztina Futosi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis

(2013) Gilbert H. Daniels et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Early development of anti-natalizumab antibodies in MS patients

(2013) B. Oliver-Martos et al.   JOURNAL OF NEUROLOGY

Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study)

(2013) J. Lycke et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

(2013) Tomas Olsson et al.   Multiple Sclerosis Journal

PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section

(2013) J. R. Berger et al.   NEUROLOGY

Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey

(2013) Raphaèle Seror et al.   RHEUMATOLOGY

Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges

(2013) Klaus Lehmann-Horn et al.   Therapeutic Advances in Neurological Disorders

The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis

(2013) Ron Milo   Therapeutic Advances in Neurological Disorders

Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study

(2012) Elizabeth V Arkema et al.   ANNALS OF THE RHEUMATIC DISEASES

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study

(2012) Marta Giannini et al.   BMC Neurology

GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study

(2012) François Curtin et al.   CLINICAL THERAPEUTICS

Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis

(2012) Yan Gan et al.   JOURNAL OF NEUROIMMUNOLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management?

(2012) C. Antoniol et al.   NEUROLOGY

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

(2011) Carmen Bozic et al.   ANNALS OF NEUROLOGY

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

(2011) A. Cuker et al.   BLOOD

Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis

(2011) Henrik Gensicke et al.   CNS DRUGS

Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE

(2011) Veit Rothhammer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: Loss of  4 Integrin Expression Differentially Affects the Homing of Th1 and Th17 Cells

(2011) S. Glatigny et al.   JOURNAL OF IMMUNOLOGY

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients

(2011) Carl E. Reid et al.   JOURNAL OF INFECTIOUS DISEASES

Progressive multifocal leukoencephalopathy and natalizumab

(2011) Kerstin Hellwig et al.   JOURNAL OF NEUROLOGY

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

(2011) Grant A Hill-Cawthorne et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Natalizumab and HSV meningitis

(2011) Erica Seiguer Shenoy et al.   JOURNAL OF NEUROVIROLOGY

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

(2011) Theo Rispens et al.   Multiple Sclerosis Journal

Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment

(2011) Kerstin Hellwig et al.   Multiple Sclerosis Journal

Herpes encephalitis during natalizumab treatment in multiple sclerosis

(2011) A Kwiatkowski et al.   Multiple Sclerosis Journal

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis

(2011) Carolina Holmén et al.   Multiple Sclerosis Journal

Hypereosinophilia in patients with multiple sclerosis treated with natalizumab

(2011) M. Abbas et al.   NEUROLOGY

Intrathecal effects of daclizumab treatment of multiple sclerosis

(2011) B. Bielekova et al.   NEUROLOGY

Immune reconstitution inflammatory syndrome in natalizumab-associated PML

(2011) I. L. Tan et al.   NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis

(2010) J. M. Fletcher et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Progressive Multifocal Leukoencephalopathy in Chronic Lymphocytic Leukemia: A Report of Three Cases and Review of the Literature

(2010) Anita D'Souza et al.   Clinical Lymphoma Myeloma & Leukemia

 4 1 Integrin Mediates the Recruitment of Immature Dendritic Cells across the Blood-Brain Barrier during Experimental Autoimmune Encephalomyelitis

(2010) P. Jain et al.   JOURNAL OF IMMUNOLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis

(2009) Bibiana Bielekova et al.   ARCHIVES OF NEUROLOGY

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

(2009) Yanping Hu et al.   IMMUNOLOGY

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

(2009) Sara A. J. Thompson et al.   JOURNAL OF CLINICAL IMMUNOLOGY

GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study

(2009) A. D. Goodman et al.   NEUROLOGY

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis

(2008) John T. Mullen et al.   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE